News ASCO26: Ivonescimab improves survival in NSCLC Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.
News Pfizer cues up vitiligo filing for Litfulo after phase 3 win Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
